Limelight Health secures $3 million in Series A funding from MassMutual Ventures

NewsGuard 100/100 Score

Limelight Health, provider of mobile enterprise technology for the health insurance industry, announced today it has received $3 million in Series A funding from MassMutual Ventures, the corporate venture capital arm of Massachusetts Mutual Life Insurance Company (MassMutual), and AXA Strategic Ventures. Also investing in the round is the series seed lead investor LaunchPad Digital Health. The company will use the funds to help grow its sales and engineering teams, to deliver innovative product enhancements to its cloud-based SaaS technology platform and aggressively expand distribution nationally.

QuotePad, Limelight Health's first commercial product released in January 2015, provides a mobile, data-driven quoting and modeling platform that enables health insurance professionals to simply and quickly quote and compare employee health insurance benefits information. QuotePad eliminates off-line, redundant, paper-based processes. It provides sufficient, real-time, analytical functionality. Brokers, carrier sales representatives and underwriters are able to immediately respond to client quote requests, model interactive plan cost scenarios and close new business sales efficiently.

"With $375 billion wasted each year on billing and health insurance paperwork, there is tremendous opportunity for the right technology solution to reduce unnecessary administrative tasks and inefficiencies in workflow," said Jason T. Andrew, CEO and co-founder, Limelight Health. "MassMutual Ventures and AXA Strategic Ventures, as partners within the insurance industry, share our vision for changing the way insurance does business, focusing our valuable resources on people, not paperwork."

"We are extremely pleased to be supporting Limelight, as they provide the brokers and employers they serve with the ability to have more meaningful and productive meetings, providing an interactive view of available health plan and contribution options, and eliminating manual back-office work," said Eric Emmons, Managing Director of MassMutual Ventures. "This will enable more efficient and effective downstream payroll and health exchange platforms."

In a short fourteen months, with initial seed investment from seed investor and accelerator Launchpad Digital Health, Limelight Health has quickly gained traction in the digital health market with its direct-source data advantage working toward becoming the hub for rate and benefit data in the U.S. With the ability to import/export health plan and contribution selections, an API/Open Integration that works with industry software applications, such as CRM, benefits administration, payroll and accounting, Limelight Health technologies are simplifying and integrating previously held manual processes, under an all-in-one, online dashboard platform.

"The SME market represents a tremendous growth opportunity for AXA in the U.S. and we have been developing new solutions to empower insurance professionals to grow their business and better serve customers through the use of multi-interactive technology," said Manish Agarwal, General Partner, AXA Strategic Ventures. "Limelight shares our vision for serving this segment of the market with technology that redefines the customer experience while bringing more transparency to business processes and we look forward to working with them to evolve the way that employee benefits are offered and understood."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations